- Home
- PLRX vs ACET Comparison
PLRX vs ACET Comparison
Compare PLRX & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | ACET |
|---|---|---|
| Founded | 2015 | 1947 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 71.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLRX | ACET |
|---|---|---|
| Price | $1.16 | $6.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $3.75 | ★ $65.33 |
| AVG Volume (30 Days) | ★ 896.1K | 201.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $6.41 |
| 52 Week High | $3.46 | $17.44 |
Technical Indicators
Market Signals| Indicator | PLRX | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 51.12 |
| Support Level | $1.09 | $6.42 |
| Resistance Level | $1.22 | $7.30 |
| Average True Range (ATR) | 0.06 | 0.62 |
| MACD | -0.00 | -0.30 |
| Stochastic Oscillator | 29.55 | 28.38 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.